Fidaxomicin for Clostridium difficile-Associated Diarrhoea

@inproceedings{Sclar2012FidaxomicinFC,
  title={Fidaxomicin for Clostridium difficile-Associated Diarrhoea},
  author={David A Sclar and Linda M. Robison and Ambartsum M. Oganov and Jennifer Maxwell Schmidt and Kurt A. Bowen and Leigh V. Castillo},
  booktitle={Clinical drug investigation},
  year={2012}
}
BACKGROUND Fidaxomicin is a macrocyclic antibiotic approved in 2011 by the US Food and Drug Administration for treatment of Clostridium difficile-associated diarrhoea (CDAD). OBJECTIVE Herein, we present an epidemiological method to estimate, on a case mix basis, and from the perspective of the US health system, the warranted (justifiable) price per day for fidaxomicin, as a percent of the wholesale acquisition cost (WAC) per day for fidaxomicin ($US280). METHODS Data from two randomized… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 11 references

FDX versus vancomycin for C. difficile infection

  • TJ Louie, MA Miller, KM Mullane
  • New Eng JMed
  • 2011
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…